Form 4: Korro Bio Insider Buys $56 Worth of Common Stock

Carmen Chang, a director of Korro Bio, indirectly acquired 17,857 shares of common stock at $56 per share on April 22, 2024, through NEA 17.

Summary

• On April 22, 2024, Carmen Chang, a director of Korro Bio, indirectly acquired 17,857 shares of common stock at a price of $56 per share.
• The transaction was made pursuant to a Subscription Agreement dated April 17, 2024.
• The shares are indirectly held through NEA 17, where Carmen Chang is a manager of NEA 17 GP, LLC, the sole general partner of NEA Partners 17, L.P., which is the sole general partner of New Enterprise Associates 17, L.P. ('NEA 17').
• Following the transaction, the total number of shares beneficially owned by NEA 17 is 1,090,793.
• Carmen Chang disclaims beneficial ownership of the securities held by NEA 17 except to the extent of any pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither positive nor negative as it simply reports a transaction.

Positives

• Insider buying can sometimes be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, as mandated by the SEC.
• The level of detail provided in this filing is consistent with industry norms for such disclosures.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it provides information about insider confidence.
• The impact on other stakeholders is likely minimal.

Key Dates